Delving into the Latest Updates on ALK2401 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

ALK2401

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Peripheral neuralgia

Inactive Indication-

Originator Organization

Alican (Hefei) Pharmaceutical Technology Co., Ltd.

Active Organization

Alican (Hefei) Pharmaceutical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of ALK2401 tablets in healthy study participants, as well as an open-label, two-period crossover study to evaluate the effect of food on the pharmacokinetics of ALK2401 tablets

主要目的：评估ALK2401片在健康研究参与者中单次、多次给药的安全性和耐受性。次要目的：1)评估ALK2401片在健康研究参与者中单次、多次给药的药代动力学特征；2)评价单次口服ALK2401片后食物对ALK2401药代动力学的影响。

[Translation]

Primary Objective: To evaluate the safety and tolerability of single and multiple doses of ALK2401 tablets in healthy study participants. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of single and multiple doses of ALK2401 tablets in healthy study participants; 2) To evaluate the effect of food on the pharmacokinetics of ALK2401 after a single oral dose of ALK2401 tablets.

Start Date-

Sponsor / Collaborator

Alican (Hefei) Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with ALK2401

Login to view more data

100 Translational Medicine associated with ALK2401

Login to view more data

100 Patents (Medical) associated with ALK2401

Login to view more data

100 Deals associated with ALK2401

Login to view more data